Yates SG, Sarode R. New strategies for effective treatment of vitamin K antagonist- associated bleeding. J Thromb Haemost 2015; 13 Suppl 1: S180-S186.Yates SG, Sarode R. New strategies for effective treatment of vitamin K antagonist-associated bleeding. J Thromb Haemost. 2015;13(Suppl 1):...
Late VKDB peaks at 3–8weeks, typically presents with intracranial haemorrhage often due to undiagnosed cholestasis with resultant malabsorption of vitamin K. Diagnosis can be difficult but PIVKA-II measurements can provide confirmation even several days post-treatment. Without vitamin K prophylaxis, ...
Vitamin K is essential for several physiological processes, such as blood coagulation, in which it serves as a cofactor for the conversion of peptide-bound glutamate to γ-carboxyglutamate in vitamin K-dependent proteins. This process is driven by the vi
Low levels of vitamin K can raise the risk of uncontrolled bleeding. While vitamin K deficiencies are rare in adults, they are very common in newborn infants. A single injection of vitamin K for newborns is standard. Doctors also use vitamin K to counteract an overdose of theblood thinnerCou...
The Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K antagonist Treatment (AVERROES) trial included 5599 patients with AF and risk factors randomized to either aspirin (81-324mg) or apixaban. Bleeding events...
Exclusion criteria were INR determined >12 hours before screening, life expectancy <10 days, need for immediate normalisation of INR, severe liver disease, major bleeding in the previous month, allergy to vitamin K, bleeding diathesis or thrombolytic treatment within 48 hours … View Full Text...
Severe bleeding in a woman heterozygous for the fibrinogen gammaR275C mutation. The dysfibrinogen gammaR275C can be a clinically silent mutation, with only two out of 17 cases in the literature reporting a hemorrhagic presentation and ... CM Rein,BL Anderson,MM Ballard,... - 《Blood Coagulati...
Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in 4 Euro- pean countries. Clin Ther. 2014;36:1160---8.Cotte FE, Benhaddi H, Duprat-Lomon I, Doble A, Marchant N, Letierce A, Huguet M. Vitamin K antagonist treatment in patients with ...
Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Patients taking oral anticoagulants with an international normalized ratio (INR) greater than 4.0 are at increased risk for bleeding. We performed a meta-a... J Kent,Dezee,T William,... - 《Archives of Inte...
14 Phenprocoumon has a longer half-life of 5.5 days compared with warfarin, with similar half-lives for both the R and S enantiomers.15 This longer half-life makes treatment of bleeding or reversal more challenging. S-phenprocoumon is 1.5–2.5 times more potent than R-phenprocoumon, and both...